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Background: With the exception of Bartonella spp. or Cytauxzoon felis, feline vector-borne pathogens (FVBP) have
been less frequently studied in North America and are generally under-appreciated as a clinical entity in cats, as
compared to dogs or people. This study investigated selected FVBP seroreactivity and PCR prevalence in cats using
archived samples.
Methods: Feline blood samples submitted to the Vector Borne Diseases Diagnostic Laboratory (VBDDL) at North
Carolina State University College of Veterinary Medicine (NCSU-CVM) between 2008 and 2013 were tested using
serological assays and PCR. An experimental SNAP® Multi-Analyte Assay (SNAP® M-A) (IDEXX Laboratories, Inc.
Westbrook, Maine, USA) was used to screen all sera for antibodies to Anaplasma and Ehrlichia genus peptides
and A.phagocytophilum, A.platys, B.burgdorferi, E.canis, E.chaffeensis, and E.ewingii species-specific peptides. PCR
assays were used to amplify Anaplasma or Ehrlichia DNA from extracted ethylenediaminetetraacetic acid (EDTA)-
anti-coagulated blood samples. Amplicons were sequenced to identify species.
Results: Overall, 7.8 % (56/715) of cats were FVBP seroreactive and 3.2 % (13/406) contained Anaplasma or
Ehrlichia DNA. Serologically, B.burgdorferi (5.5 %) was the most prevalent FVBP followed by A.phagocytophilum
(1.8 %). Ehrlichia spp. antibodies were found in 0.14 % (12/715) of cats with species-specific seroreactivity to
E.canis (n = 5), E.ewingii (n = 2) and E.chaffeensis (n = 1). Of seropositive cats, 16 % (9/56) were exposed to more
than one FVBP, all of which were exposed to B.burgdorferi and either A.phagocytophilum (n = 7) or E.ewingii (n = 2).
Based upon PCR and DNA sequencing, 4, 3, 3, 2, and 1 cat were infected with A.phagocytophilum, A.platys, E. ewingii, E.
chaffeensis and E.canis, respectively.
Conclusions: Cats are exposed to and can be infected with vector-borne pathogens that commonly infect dogs and
humans. To our knowledge, this study provides the first evidence for E.chaffeensis and E.ewingii infection in naturally-
exposed cats in North America. Results from this study support the need for regional, serological and molecular FVBP
prevalence studies, the need to further optimize serodiagnostic and PCR testing for cats, and the need for prospective
studies to better characterize clinicopathological disease manifestations in cats infected with FVBP.
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In North America, fleas, mosquitoes and ticks are con-
sidered the most important vectors for transmission of a
spectrum of infectious agents that can induce disease in
mammalian species, including dogs and humans; however,
with the exceptions of Dirofilaria immitis (mosquito-borne
feline heartworm disease) [1], Cytauxzoon felis (tick-borne
feline cytauxzoonosis) [2] and Bartonella henselae (flea or
tick-borne feline bartonellosis) [1], other known canine
and human tick-borne pathogens have not been detected
in, or have been minimally studied, in cats in the US and
throughout much of the world when compared to dogs or
humans. Anaplasma, Borrelia and Ehrlichia species infect
cows, sheep, dogs, horses and human beings; however, the
role of these pathogens as a cause of disease in cats re-
mains incompletely defined [3]. As compared to dogs and
humans, the smaller number of FVBP studies may be due
to the lack of standardized serological tests, either ELISA
or IFA, as are used routinely in canine veterinary practices.
Also, veterinarians’ perception of the risk of FVBD may be
a factor because there have been fewer research studies
defining the regional serological or PCR prevalence of
anaplasmosis, ehrlichiosis, and Lyme disease in cats. This
factor is undergoing rapid change as researchers around
the world have begun to investigate FVBP prevalence
among various cat populations (feral, healthy, sick, etc.).
Serological, and to a lesser extent molecular-based, FVBP
studies have been reported from the US [4–6], Brazil
[7–9], France [10], Portugal [11], Italy [12] Spain [13, 14],
Sweden [15], Kenya [16], and the Far East [17, 18]. In
parts of Spain and Italy, stray and domestic cat A.phagocy-
tophilum seroprevalence rates ranged from 2–8 % [7, 19,
20]. In the US, A.phagocytophilum seroprevalences range
from 4.3 % [6] in southeastern US to as high as 38 % in
northeastern US endemic regions [5]. E.canis seropreva-
lence rates have ranged from 6–18 % in Europe [7, 13, 14,
19, 20]. In the Western hemisphere fewer Ehrlichia spp.
seroprevalence studies have been performed; however,
E.canis seroprevalence was 5.5 % amongst 200 domestic
cats in Brazil [8]. B.burgdorferi seroprevalence rates as
high as 47 % were found in cats from areas endemic for
Lyme in the US [5]. Currently, veterinary diagnostic sero-
logical assays rely upon A.phagocytophilum, B.burgdorferi
and E.canis antigens and assays that were originally vali-
dated for testing dogs and in most instances have not been
optimized for testing cats.
Molecular-based evidence, such as PCR, indicates that
cats can potentially be infected with A.phagocytophilum
[4, 12, 15], A.platys [21, 22] and E.canis [9, 11, 23–25].
In Sweden, Bjoersdorff et al. was first to report PCR
amplification of A.phagocytophilum from a cat [15]. The
DNA sequence in a 14-month-old shorthaired cat with leth-
argy and fever was 100 % identical to dog and horse A.
phagocytophilum strains from the same region. Subsequently,Lappin et al. confirmed infection with A.phagocytophilum in
5 young clinically-ill cats from the northeastern US by PCR
amplification and DNA sequencing [4]. To date, A.platys in-
fections, with PCR amplification of the pathogen, have been
reported in only two thrombocytopenic cats [21, 22]. Other
clinical manifestations included anorexia and platelet inclu-
sion bodies in a cat from Brazil [21] and chronic hyperglobu-
linemia in a cat from North Carolina that was also PCR
positive for Mycoplasma hemominutum, Bartonella henselae
and Bartonella koehlerae [22]. Using PCR, Ehrlichia species
DNA has been amplified from cats located in Italy [12],
France [10, 23] and the Americas [8, 9, 23–25]. DNA evi-
dence of possible E.canis (98 % identity) and E.chaffeensis
(97 % identity) infections was reported by Braga Mdo et al.
in cats from Brazil [8]. Positive E.canis PCR results were
also reported for 11 thrombocytopenic and lymphopenic
Brazilian cats [9, 25]. Based upon PCR amplification
and DNA sequencing of the Ehrlichia 16S rDNA
gene, our research group described E.canis infection
(100 % identical to E.canis DNA obtained from dog
isolates) in cats from France [23] and in 3 young, sick
cats from the southeastern United States or eastern
Canada [24].
IDEXX Laboratories, Inc. (Westbrook, Maine, USA)
developed a qualitative enzyme-linked immunosorbent
assay (ELISA) test, SNAP® M-A, using Anaplasma genus
EENZ1 and Ehrlichia genus p30/p30-1 peptides to broadly
detect Anaplasma spp. and Ehrlichia spp. antibodies in
conjunction with A.phagocytophilum p44 Aph, A.platys
p44 Apl, E.canis p16, E.chaffeensis VLPT, E.ewingii p28,
and B.burgdorferi C6 species-specific peptides as a research
tool to characterize regional trends in seroprevalence to
specific vector-borne pathogens in dogs [26, 27]. Although
developed as a canine assay, the assay does not use a host
species-specific conjugate, and can therefore be used
on a research basis to screen mammalian species other
than dogs. An earlier ELISA based assay, the SNAP® 3Dx®,
was used in a serosurvey of cats naturally exposed to
B.burgdorferi [28] and the SNAP®4Dx® has been utilized to
test horses for borreliosis [29] and ehrlichiosis [30, 31].
Recently, Qurollo et al. reported seroprevalence data
using SNAP® M-A in over 6500 archived canine serum
samples from the US, Canada and the Caribbean. Over-
all and regional seroprevalence and co-seroprevalence
(exposure to more than one pathogen) was determined,
as well as seroprevalence trends between 2008 and 2010
[26]. Although currently SNAP® M-A is not available
commercially, the use of a broad range of genus and
species-specific immunodominant peptides in diagnos-
tic tests would allow veterinarians to determine Ana-
plasma or Ehrlichia species exposures in dogs and cats
in their region. This information could benefit both
clinical decision making, as well as human and veterin-
ary zoonotic disease education [32–34].
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of FVBPs in cats suspected of exposure to a vector-borne
pathogen. Specifically, we determined the seroprevalence
of Anaplasma spp., B.burgdorferi and Ehrlichia spp. and
the presence of Anaplasma or Ehrlichia sp. DNA, as
determined by PCR amplification and DNA sequencing.
Methods
All samples were de-identified, so no ethical approval
necessary.
Clinical accessions and sample availability
Feline clinical accessions (n = 858) submitted to the NCSU-
CVM-VBDDL between January 1, 2008, and December 31,
2013, for FVBP testing originated from veterinary hospitals
located in the United States (n = 827), Canada (n = 28) and
the Caribbean (n = 3). Sample submission information in-
cluded date of collection, date received, and the cat owner
or veterinary practice address while individual identifica-
tions were not revealed. Of these 858 cats, 715 sera were
available for testing using the SNAP® M-A kit for Ana-
plasma, Borrelia, and Ehrlichia antibodies and EDTA-anti-
coagulated whole blood was available from 406 cats for
PCR testing. Prior to the study, Anaplasma and Ehrlichia
diagnostic PCR results were known for 163 of these
406 cats. Stored, frozen (−80 °C) blood was retrievable
for additional PCR testing for 331/406 diagnostic acces-
sions. When adequate serum volumes were available, a
subset of 59 SNAP® M-A seropositive and 4 PCR positive
samples were tested by SNAP®4Dx®Plus assay (IDEXX
Laboratories, Inc. Westbrook, Maine, USA) and by in-
direct fluorescent antibody (IFA) assays using whole cell
antigens. Medical record data was obtainable for 7 PCR
positive cats, 4 of which were referrals to the NC State
Veterinary Hospital and 3 were from other veterinary hos-
pitals or universities. Medical records were reviewed for
the signalment, history and physical examination findings,
complete blood count (CBC), serum biochemistry profile
abnormalities and for additional diagnostic testing that
were performed, including abdominal ultrasound, radio-
graphs, or coagulation profiles.
Serological assays
Cat serum specimens (n = 715) were retrospectively tested
by SNAP® M-A for A.phagocytophilum, A.platys, B.burg-
dorferi, E.canis, E.chaffeensis, and E.ewingii antibodies.
This kit uses a reversible chromatographic flow of sample
and automatic, sequential flow of wash solution and en-
zyme substrate. Archived cat serum stored at − 80 °C
was thawed to room temperature prior to mixing 4 drops
of serum with 4–5 drops of SNAP® M-A conjugate. The
mixture was allowed to move across a flow matrix where
peptide-specific antibody could bind to peptide-horse rad-
ish peroxidase conjugate before color reactant release.Color development, indicating a positive reaction, was
read after 15 min per manufacturer’s instructions (IDEXX
Laboratories, Inc, Westbrook, Maine, USA).
PCR testing
DNA from 200 μL of feline EDTA-anti-coagulated whole
blood was extracted with a QIAsymphony™ robotic ex-
tractor using MagAttract® DNA Mini M48 kit (Qiagen,
USA cat: 953336). DNA quality was assayed by quantita-
tive PCR (qPCR) amplification of the glyceraldehyde
3-phosphate dehydrogenase gene on feline genomic
DNA. A conventional PCR assay targeting a conserved
region of the Anaplasma and Ehrlichia 16S rRNA gene
[35] and two qPCR assays targeting the Anaplasma genus
Tr-1 and Ehrlichia genus sodB [36] genes were performed
on stored, frozen blood samples (n = 331). Species were
identified by amplicon sequencing (Genewiz, Research
Triangle Park, NC, USA) and additional, species-specific
qPCRs were used in an attempt to confirm positive
samples. The Anaplasma genus Tr-1 assay and species-
specific assays (A.phagocytophilum p44, A.platys p44,
E.chaffeensis nadA, and E.ewingii sodB) used in this
study have not been previously reported; primer sequence
and amplicon size for each of these qPCRs are listed in
Table 1. The reactions were performed in a CFX96™ Real-
Time Detection System combined with C1000™ Thermal
Cycler (Bio-Rad, USA) under the following conditions:
25 μl final volume reaction containing 12.5 μl of SYBR®-
Green Supermix, 0.2 μM of the Tr-1 primers and 0.3 μM
of each species-specific primer (Sigma-Aldrich, St Louis,
MO, USA), 7 μl of filter-sterilized, molecular-grade water
and 5 μl of DNA template. Thermocycler conditions con-
sisted of a single cycle at 98 °C for 2 min, followed by
40 cycles of denaturation at 98 °C for 15 s, annealing at
57 °C (Tr-1) or 67 °C (all species-specific assays) for 15 s,
and extension at 72 °C for 15 s. Melting temperature mea-
surements were made between 65–88 °C at 0.5 s intervals.
Comparison of serological assays
Fifty-nine stored, frozen sera from SNAP® M-A sero-
positive and/or PCR positive cats were retested using
the SNAP®4Dx®Plus assay (IDEXX Laboratories, Inc.
Westbrook, Maine, USA) according to manufacturer’s
directions. SNAP® M-A and PCR positive cats were also
tested by IFA using A.phagocytophilum (ProtaTek Inter-
national Inc. St. Paul, MN, USA), E.canis (strain NC Jake),
E.chaffeensis (strain E.chaffeensis Ark) and B.burgdorferi
(MBL Bion, Des Plaines, IL, USA) antigen slides as appro-
priate for the seroreactivity detected by SNAP® M-A. For
IFA testing, serum samples were diluted two fold from
1:16 to 1:512 in phosphate buffered saline (PBS) solution
containing 1 % normal goat serum, 0.05 % Tween-20 and
0.5 % powdered nonfat dry milk (BioRad, Hercules, CA,
USA). Antibody responses were detected by IFA with
Table 1 Primer targets, sequences and amplicon base pair size for previously unreported quantitative PCR assays used in this study.
F: Forward primer; R: reverse primer
Target Primers Amplicon (bp)
Anaplasma -tr-1 F- 5′ ATGTTTATGACTTCTCAAGCAC-3′ R- 5′ CCC TTT TCG TAT TTT TGT AC-3′ 200
A. phagocytophilum -p44 F- 5′ TGGTGGTGCGGGATATTTCTATGTTG-3′ R- 5′ CCCAATCCGAGGATCAGGTGTG-3′ 179
A. platys -p44 F- 5′ GCT AAG TGG AGC GGT GGC GAT GAC AG-3′ R- 5′ GCCGCAGTTTCCCCGGTACT-3′ 179
E. chaffeensis -nadA F- 5′ CGCAAAAGATGTAATTCTTTGGGAATC-3′ R- 5′ CACCTCAAAATCAGAATTCATCGAAGG-3′ 117
E. ewingii -sodB F- 5′ GCTGGAATAGGTCATTTTGGTAGTGGA-3′ R- 5′ GTTCCCATACATCCATAGCAAGCAAC-3′ 147
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Scientifics, Waltham, MA, USA) [37]. Seropositive sam-
ples were defined as having endpoint titers ≥ 1:64 based
upon laboratory criteria used by the VBDDL.Results
Seroreactivity
Of the 715 cat serum samples tested with SNAP® M-A,
the overall FVBP seroprevalence (Table 2) was 7.8 %
(56/715) with B.burgdorferi the most seroprevalent at
5.5 % (39/715). By SNAP® M-A testing, seroreactivity to
an Anaplasma or Ehrlichia spp. peptide was detected in
2.9 % (21/715) of cat serum accessions tested. Based upon
the 3 Anaplasma spp. analytes, 1.8 % of cats (13/715) were
exposed to an Anaplasma spp., of which 12 were A.phago-
cytophilum seroreactive and one cat was seroreactive with
only the genus analyte. No cat was SNAP® M-A A.platys
seroreactive. Using SNAP® M-A, Ehrlichia genus seroreac-
tivity was found in 1.7 % (12/715) of cats. Based upon re-
activity to a species-specific peptide, 5 of the 12 cats were
seroreactive to E.canis (0.7 %), 2 cats to E.ewingii (0.3 %),1
cat to E.chaffeensis (0.2 %) and 4 cats were seroreactive
with only the genus analyte. Seroreactivity to more than
one FVBP was found in 16.1 % (9/56) of seroreactive cats.
For each of these 9 cats, B.burgdorferi seroreactivity
was detected in conjunction with either A.phagocytophilum
(n = 7) or E.ewingii (n = 2) seroreactivity.Table 2 Regional Seroprevalence by SNAP® M-A shown as percenta
Regions Anapl genus Aph Apl
Northeast n = 187 (26 %) 2a 9 (6a) 0
Mid Atlantic n = 59 (8 %) 2 (1a) 2 0
South n = 284 (40 %) 1 1 0
Midwest n = 114 (16 %) 0 1 0
West n = 42 (6 %) 0 0 0
Canada n = 26 (4 %) 0 0 0
Caribbean n = 3 (0.4 %) 0 0 0
Total n = 715 5 (0.7 %) 13 (1.8 %) 0
aindicates co-exposures
Anapl genus: Anaplasma genus; Aph: A.phagocytophilum; Apl: A.platys; Bb: Borrelia bu
Eew: E.ewingiiPCR amplification of Anaplasma and Ehrlichia
Based upon conventional Anaplasma and Ehrlichia 16S
rDNA PCR diagnostic results, performed at the time of
sample submission to the VBDDL (n = 163), 7 cats were
infected with either A.phagocytophilum (n = 4), A.platys
(n = 2), or E.canis (n = 1). When archived frozen EDTA-
whole blood (n = 331) was accessed for testing by 16S
rDNA PCR, 7 cats were infected with either an Ana-
plasma or Ehrlichia spp., including E.ewingii (n = 3),
E.chaffeensis (n = 2), A.phagocytophilum (n = 1) and
A.platys (n = 1). Based upon diagnostic and archival PCR
testing, the total number of cats infected with an Ana-
plasma or Ehrlichia sp. was 3.2 % (13/406), with one
A.phagocytophilum PCR positive cat represented in both
the diagnostic and archival PCR results (Table 3). Add-
itional retrospective Anaplasma and Ehrlichia genus-
and species-specific PCRs confirmed several 16S rDNA
PCR positive samples, and included cats infected with
A.phagocytophilum, E.chaffeensis, and E.ewingii (Table 3).
Clinical data
Clinical data for 7 PCR positive cats is summarized in
Table 4. The FVBP PCR positives for which records were
available included 3 A.platys infected cats, one of which
was a cat diagnosed with multiple myeloma, as previously
described in a case report [22], 2 A.phagocytophilum in-
fections, 1 E.chaffeensis infection (limited to CBC and bio-
chemistry panel), and 1 E.ewingii infection. Four of the 6ges of 715 feline serum samples
Bb Ehrl genus Ec Ech Eew
26 (6a) 0 2 0 0
10 (3a) 1 0 0 2a
1 3 1 1 0
1 1 0 0 0
0 0 1 0 0
0 0 1 0 0
1 0 0 0 0
39 (5.5 %) 5 (0.7 %) 5 (0.7 %) 1 (0.2 %) 2 (0.3 %)
rgdorferi; Ehrl genus: Ehrlichia genus; Ec: E.canis; Ech: E.chaffeensis;
Table 3 State of origin, VBDDL diagnostic and archived sample Anaplasma and Ehrlichia PCR results, SNAP® M-A, SNAP® 4Dx®Plus
and IFA (antigen) serology results for individual cats infected with FVBD




PCR on archived samples
(gene targets)
SNAP® M-A SNAP® 4Dx® Plus IFA (Ech) IFA (Ec) IFA (Aph) IFA (Bb)
1 NC Apl (16S, GroEL, p44) N/A (−) N/A N/A N/A N/A N/A
2 OH Apl (16S) N/A N/A N/A N/A N/A N/A N/A
3 NC ND Apl (16S) N/A N/A N/A N/A N/A N/A
4 MI Aph (16S) (−) N/A N/A N/A N/A N/A N/A
5 MA Aph (16S) (−) N/A N/A N/A N/A N/A N/A
6 NC Aph (16S) (−) N/A N/A N/A N/A N/A N/A
7 NY Aph (16S) Aph (16S, tr-1, p44) Bb+ Bb+ 64 <16 <16 32
8 VA Ec (16S) (−) N/A N/A N/A N/A N/A N/A
9 NC (−) Ech (16S) (−) (−) <16 <16 <16 128
10 MO ND Ech (16S, sodB, nadA) (−) (−) <16 128 <16 16
11 SC (−) Eew (16S) (−) (−) <16 <16 <16 16
12 CA (−) Eew (16S) (−) (−) <16 <16 <16 <16
13 NC (−) Eew (16S, sodB) N/A N/A N/A N/A N/A N/A
Aph: A.phagocytophilum; Apl: A.platys; Ec: E.canis; Ech: E.chaffeensis; Eew: E.ewingii; Bb: B.burgdorferi; FVBD: feline vector-borne disease; ND: not done; N/A: Archived
Serum or EDTA-whole blood was not available; (−): negative serology or PCR result
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only, one unknown, and one cat had a tick removed im-
mediately prior to becoming ill. Presenting complaints
included anorexia, lethargy or epistaxis. Three cats were fe-
brile at the time of physical examination and one cat was
icteric, however this cat was co-infected with Cytauxazoon
felis and A.platys. Feline Leukemia and Feline Immunodefi-
ciency Virus (FeLV/FIV) results were negative for 6 of 6
cats tested. The most common hematological abnormal-
ities included anemia (n = 5), thrombocytopenia (n = 5) and
neutrophilia (n = 3). Other blood abnormalities reported
by the attending veterinarian included hyperglobulinemia,
lymphocytosis or thrombocytosis. One E.ewingii positive
cat was found to be hyperthyroid.
Comparison among serological assays
Fifty-nine SNAP® M-A positive serum samples had suffi-
cient volume for SNAP®4Dx®Plus and/or IFA comparative
testing. Of the 13 cats that were seroreactive to SNAP®
M-A Anaplasma sp. analytes (EENZl and P44 Aph),
only 3 (23 %) were seroreactive by SNAP®4Dx®Plus
(EENZ1 analyte), whereas 11 (85 %) were IFA positive
for A.phagocytophilum antibodies. When compared to
the SNAP® M-A Ehrlichia sp. analytes (p30/p30-1, p16,
VLPT, p28), there was variable agreement with the
SNAP®4Dx®Plus and E.chaffeensis or E.canis IFA using
whole cell antigen preparations (Table 5). By E.chaffeen-
sis IFA, only one E.chaffeensis and one Ehrlichia genus
reactive cat were seropositive at titers of 1:256 and 1:64,
respectively. Only the E.chaffeensis IFA seroreactor was
E.canis IFA seroreactive at a titer of 1:256. None of the
five SNAP® M-A E.canis p16 reactors were positive bySNAP®4Dx®Plus (p16 not present in this assay) or by
IFA testing using E.chaffeensis or E.canis whole cell an-
tigens. Of the 39 SNAP® M-A B.burgdorferi C6 peptide
positives, 23 (59 %) and 27 (69 %) were positive by
SNAP®4Dx®Plus or a whole cell B.burgdorferi antigen
preparation, respectively.
Serum samples, available for 4 PCR positive cats, (2
E.chaffeensis and 2 E.ewingii) were not seroreactive by
any of the three serological assays with the exception of
an antibody response of 1:128 against E.canis by IFA for
a cat that was PCR positive for E.chaffeensis (Table 3). A
serum sample available from a fifth cat PCR positive for
A.phagocytophilum was reactive to the C6 B.burgdorferi
analyte in both SNAP® M-A and SNAP®4Dx®Plus but was
not reactive to any A.phagocytophilum antigens.
Discussion
To the authors’ knowledge, this is one of the largest fe-
line tick-borne pathogen prevalence studies reported for
cats suspected of vector-borne infections from North
America. Using species-specific peptides or PCR testing,
this study identified two tick-borne pathogen species
(E.chaffeensis and E.ewingii) that to our knowledge have
not been previously reported to infect cats in North
America. In addition, antibodies to B.burgdorferi (5.5 %)
and A.phagocytophilum (1.8 %) were found frequently in
serum submitted from sick cats in Lyme disease endemic
regions of the northeastern and mid-Atlantic United States.
These two pathogens share a common vector, Ixodes
scapularis. Similarly, B.burgdorferi and A.phagocytophilum
co-exposures were the most frequently detected. While
exposure to, or infection with, a spectrum of FVBP were
Table 4 Abbreviated clinical data available for 7 Anaplasma or Ehrlichia PCR positive cats
Cat# FVBD Sig. Presenting complaint Abnormal PE findings Hematological Additional findings
1 Apl 11y MC DSH chronic hyper-globulinemia none reported mod. hyperglobulinemia, mld.
thrombocytopenia mld. anemia
indr/outdr; FeLV/FIV (−); co-infection with
Mh, Bh, and Bk; dx. with multiple myeloma*
2 Apl 3y MC DSH lethargy, pallor pale, febrile (103.5 °C), heart
murmur (IV/VI)
svr. anemia, mld leukocytosis
mod. lymphocytosis
indr/outdr; FeLV/FIV (−); saline ag.(−); imaging:
enlarged heart and mld. free fluid in thoracic
and abdominal cavities; BM aspirate erythiroid
hyperplasia and dysplasia, lymphoid hyperplasia;
dx. PRCA or infection or CLL.
3 Apl 5y FS DMH anorexia, lethargy, C. felis (+) icteric, febrile (103.2 °C) svr. anemia, mld. leukopenia
mod. thrombocytopenia, mld.
hyperproteinemia
indr/outdr; FeLV/FIV (−); normal coag-ulation
(PT/PTT); co-infection C. felis
6 Aph 8 m MC DSH lethargy, persistent leukocytosis none reported mod. neutrophilia, mod.
lymphocytosis, mod.
thrombocytosis
indr; FeLV/FIV (−); imaging WNL
7 Aph 9y MC DSH lethargy, inappetance lethargic, febrile (103.5 °C) mld. anemia, mod. thrombocytopenia
mod. neutrophilia mod. lymphopenia
indr/outdr; tick removed recently; FeLV/FIV (−);
normal coagulation (PT/PTT)
9 Ech 11y MC DSH ND ND WNL ND
13 Eew 12y MC DSH chronic intermittent epistaxis epistaxis thyroid nodule mod. anemia mld. neutrophilia svr.
thrombocytopenia elevated T4
indr/outdr; FeLV/FIV (−); normal coagulation (PT/PTT);
imaging WNL
Aph: A.phagocytophilum; Apl: A.platys; Ech: E.chaffeensis; Eew: E.ewingii; PE: physical examination; MC: male castrated; FS: female spayed; DS(M)H: domestic short (medium) hair; mld: mild; mod: moderate; svr: severe;
indr: indoor; outdr: outdoor; WNL: within normal limits; ND: no data; FeLV: Feline Leukemia Virus; FIV: Feline Immunodeficiency Virus; BM: Bone Marrow; PRCA: pure red cell aplasia; CLL: Chronic Lymphoid Leukemia;












Table 5 Comparison of SNAP® M-A results for 59 sera with SNAP®4Dx®Plus and Anaplasma phagocytophilum, Ehrlichia chaffeensis,
Ehrlichia canis, or Borrelia burgdorferi Immunofluorescence results
# SNAP® M-A positive # SNAP®4Dx®Plus positive # IFA seroreactive ≥ 64
SNAP® M-A Analyte A.phagocytophilum
A. genus eenz1 5 3/5 3/5
Aph p44 aph 12 3/12 9/12
Apl p44 apl 0 0 0
E.chaffeensis E.canis
E. genus p30/p30-1 5 4/5 2/5 1/5
Ec p16 5 0/5 0/5 0/5
Ech VLPT 1 1/1 1/1 1/1
Eew p28 2 1/2 1/2 0/2
B.burgdorferi
Bb C6 39 23/39 27/39
IFA: immunofluorescent assay; A.genus: Anaplasma spp.; E.genus: Ehrlichia spp.; Aph: A. phagocytophilum; Apl: A.platys; Ec: E.canis; Ech: E.chaffeensis; Eew: E.ewingii;
Bb: B. burgdorferi
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PCR prevalence of tick-borne infections were relatively
low compared to dogs tested during a similar time frame
[26, 38]. For example, using SNAP® M-A to test over 6500
dog serum samples submitted to the NCSU-CVM-VBDDL
from the United States, Canada and the Caribbean, pri-
marily between 2008 and 2010, the overall canine sero-
prevalence was 8.3 % for B.burgdorferi and 3.4 % for
A.phagocytophilum, both nearly double the prevalences
in cats [26]. Reasonable explanations for the lower
FVBP seroprevalences include shorter tick-attachment
times due to fastidious grooming, thus reducing the op-
portunity for pathogen transmission. Also, although
demographic and environmental data was not available
for these diagnostic accessions, the cats included in this
study were likely client-owned and therefore were more
likely to be maintained primarily indoors and thus ex-
posed to fewer ticks than their canine counterparts.
Historical or more recent documentation of exposure
to, or infections with, A.platys, E.canis, E.chaffeensis and
E.ewingii in cats provides a justification for future stud-
ies that investigate specific disease presentations associ-
ated with each of these infections. Similar to dogs, cats
can be sequentially or concurrently exposed to more than
one FVBP; therefore, co-infections can influence clinical,
hematological and pathological findings [26]. In this study,
complete or partial medical data obtained for 7 PCR
positive cats (Table 4) underscores potential clinical and
hematological disease similarities among cats and dogs
in association with vector-borne infectious diseases. For
example, four of seven cats were anemic and thrombocyto-
penic and epistaxis was reported in one of the markedly
thrombocytopenic E.ewingii infected cats. Also, two
A.platys infected cats were thrombocytopenic; however, co-
infections were detected in both cats, so it is impossible toknow the degree to which the A.platys infection contrib-
uted to thrombocytopenia in either cat.
In conjunction with published and ongoing studies of
cat populations throughout the world, expanded FVBP
test offerings by diagnostic laboratories are warranted.
The sensitivity of a serological test is contingent upon
the type, configuration and specificity of peptides chosen
in the design of the assay. In addition, it should be deter-
mined if cats’ immunological reactivity to currently used
diagnostic peptides is the same or different than dogs.
Although assays being used in canine VBD diagnostic
panels, whether ELISA or IFA based, will be a first step
in facilitating the detection of FVBP in cats, improvements
are in order. As an example, five cats were seroreactive
using the E.canis p16 peptide, whereas none of these 5
cats were seroreactive by SNAP®4Dx®Plus (p16 not present
in this assay) or by IFA testing using E.chaffeensis or
E.canis whole cell antigens. Whether this discrepancy rep-
resents a lack of specificity of the p16 analyte, a lack of
sensitivity of the commercial ELISA and IFA, or enhanced
analytical sensitivity of this analyte for testing cat sera re-
mains to be determined. Also, only one of the E.chaffeensis
or E.ewingii infected cats (PCR+ with DNA sequence con-
firmation) was seroreactive, using any of the three assays
assessed in this study. If as a general rule applicable to tick
exposed cats, this finding could contribute to falsely low
Ehrlichia seroprevalences, both diagnostically and during
cat serosurvey studies. Isolation of FVBP from cats in con-
junction with the detailed characterization of immuno-
logic response to specific antigens may lead to assays that
are more specific and hopefully more sensitive in the
clinical diagnosis of acute or chronic vector-borne diseases
in cats. The combination of serology and PCR testing has
been recommended for the evaluation of canine VBDs
[39]. Based upon the results of this study, using panels
Hegarty et al. Parasites & Vectors  (2015) 8:320 Page 8 of 9combining serology, with IFA being demonstrated as
slightly more sensitive than ELISA in this study for A.pha-
gocytophilum, Ehrlichia spp., and B.burgdorferi, along with
genus and species-specific PCR in cats seems warranted,
as this approach would facilitate more accurate diagnoses
and targeted therapy for sick cats.
There were several inherent limitations to this study.
The cat serum and blood specimens submitted by veteri-
narians to the VBDDL were from cats presumably sus-
pected of an infection with a FVBP. However, based upon
the historical research priorities of our laboratory, it is
likely that many of these specimens were submitted from
cats in which cytauxzoonosis (C. felis transmitted by ticks)
or bartonellosis (Bartonella henselae and other Bartonella
sp. most often transmitted by fleas) were suspected. Thus,
seroprevalence rates in these cats are presumably higher
than in the healthy, client-owned cat population. Although
cats were regionalized based on local veterinary hospitals
or owner zip codes, individual travel histories were not
available; therefore, where exposures or infections occurred
remains uncertain. Also, as medical histories were not pro-
vided in conjunction with sample submission information,
it was not possible to determine risk factors such as out-
door exposure potential (living primarily indoors, indoors
and outdoors, or outdoors only), vector exposure and other
environmental factors that would influence the prevalence
results. Despite obtaining clinical data for 7 PCR positive
cats; incomplete medical record entries, variability in the
clinical data obtained for each cat and the documentation
of co-infections in two cats, does not allow specific clinical
or hematological abnormalities to be attributed to infection
with a specific FVBP.
Conclusions
Cats are exposed to and can be infected with vector-borne
pathogens that commonly infect dogs and humans. Ana-
plasma phagocytophilum, A.platys, E.canis, E.chaffeensis
and E.ewingii infections were confirmed by PCR ampli-
fication and DNA sequencing. To our knowledge, this
study provides the first evidence for E.chaffeensis and
E.ewingii infection in naturally-exposed cats in North
America. Results from this study support the need for
regional, serological and molecular FVBP prevalence
studies, the need to further optimize serodiagnostic and
PCR testing for cats, and the need for prospective stud-
ies to better characterize clinicopathological disease
manifestations in cats infected with FVBP.
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